Abstract
Small interfering RNAs (siRNA) are emerging as a new opportunity for treatment of various diseases, including viral and cancer diseases via knocking down a specific gene that involves in disease development. But their clinical application is hampered because of susceptibility to degradation and difficult delivery of siRNA into cells. So it is needed to develop an efficient carrier that stabilizes and delivers siRNA efficiently and specifically into cells. Hollow inorganic nanoparticles have gained considerable attention as an efficient drug and gene delivery system. This is due to their biocompatibility, simple preparative processes, easy functionalization and high capacity for drug loading. Several nanoparticle platforms for siRNA delivery have been developed to overcome the major limitations facing the therapeutic uses of siRNA. Recently, researchers have developed a wide range of inorganic nanocarriers to increase efficacy of si-RNA-based drugs and gained efficient siRNA delivery both in vitro and in vivo. This review covers a broad spectrum of hollow inorganic nanoparticles as non-viral siRNA delivery systems. These nanoparticles are developed for enhanced cellular uptake and targeted gene silencing in vitro and in vivo and their characteristics and opportunities for clinical applications of therapeutic siRNA are discussed in this article. Various types of inorganic hollow nanovectors including: mesoporous silica nanoparticles, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles, hollow manganese oxide, gold nanoshells, and layered double hydroxide nanoparticles used to deliver siRNA are introduced and the development of theranostics and combinational treatment is also discussed.
Keywords: Hollow nanoparticles, inorganic, siRNA, mesoporous silica, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles.
Current Pharmaceutical Design
Title:Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Volume: 21 Issue: 29
Author(s): Jaleh Varshosaz and Somayeh Taymouri
Affiliation:
Keywords: Hollow nanoparticles, inorganic, siRNA, mesoporous silica, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles.
Abstract: Small interfering RNAs (siRNA) are emerging as a new opportunity for treatment of various diseases, including viral and cancer diseases via knocking down a specific gene that involves in disease development. But their clinical application is hampered because of susceptibility to degradation and difficult delivery of siRNA into cells. So it is needed to develop an efficient carrier that stabilizes and delivers siRNA efficiently and specifically into cells. Hollow inorganic nanoparticles have gained considerable attention as an efficient drug and gene delivery system. This is due to their biocompatibility, simple preparative processes, easy functionalization and high capacity for drug loading. Several nanoparticle platforms for siRNA delivery have been developed to overcome the major limitations facing the therapeutic uses of siRNA. Recently, researchers have developed a wide range of inorganic nanocarriers to increase efficacy of si-RNA-based drugs and gained efficient siRNA delivery both in vitro and in vivo. This review covers a broad spectrum of hollow inorganic nanoparticles as non-viral siRNA delivery systems. These nanoparticles are developed for enhanced cellular uptake and targeted gene silencing in vitro and in vivo and their characteristics and opportunities for clinical applications of therapeutic siRNA are discussed in this article. Various types of inorganic hollow nanovectors including: mesoporous silica nanoparticles, carbon nanotubes, graphene oxide, fullerenes, calcium phosphate nanoparticles, hollow manganese oxide, gold nanoshells, and layered double hydroxide nanoparticles used to deliver siRNA are introduced and the development of theranostics and combinational treatment is also discussed.
Export Options
About this article
Cite this article as:
Varshosaz Jaleh and Taymouri Somayeh, Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review, Current Pharmaceutical Design 2015; 21 (29) . https://dx.doi.org/10.2174/1381612821666150901103937
DOI https://dx.doi.org/10.2174/1381612821666150901103937 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Brain-Derived Neurotrophic Factor: A Common Link Between Neurodegenerative Disorders and Cancer?
Current Alzheimer Research Anti-Cancer Compounds from Terrestrial and Marine Resources -In silico and Experimental Studies
Current Computer-Aided Drug Design Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Cellular Senescence-Inducing Small Molecules for Cancer Treatment
Current Cancer Drug Targets Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Insights into Cellular Uptake of Nanoparticles
Current Drug Delivery Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism Meet Our Editorial Board Member
Current Cancer Therapy Reviews Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design A Sialic Acid-Specific Lectin from the Mushroom Paecilomyces Japonica that Exhibits Hemagglutination Activity and Cytotoxicity
Protein & Peptide Letters Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics